A Phase 1b/2 First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b.
Kolejna witryna oparta na WordPressie
PARTNERZY
PARTNERZY
A Phase 1b/2 First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b.